Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming.
NPJ Vaccines
; 9(1): 58, 2024 Mar 11.
Article
en En
| MEDLINE
| ID: mdl-38467663
ABSTRACT
Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8 60mer germline-targeting immunogen, higher frequencies of vaccine-induced VRC01-class bnAb-precursor B cells were observed in the high dose compared to the low dose group. Through immunoglobulin heavy chain variable (IGHV) genotyping, statistical modeling, quantification of IGHV1-2 allele usage and B cell frequencies in the naive repertoire for each trial participant, and antibody affinity analyses, we found that the difference between dose groups in VRC01-class response frequency was best explained by IGHV1-2 genotype rather than dose and was most likely due to differences in IGHV1-2 B cell frequencies for different genotypes. The results demonstrate the need to define population-level immunoglobulin allelic variations when designing germline-targeting immunogens and evaluating them in clinical trials.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
NPJ Vaccines
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos